MX2021013612A - Composiciones de oligosacaridos y metodos de uso de las mismas. - Google Patents

Composiciones de oligosacaridos y metodos de uso de las mismas.

Info

Publication number
MX2021013612A
MX2021013612A MX2021013612A MX2021013612A MX2021013612A MX 2021013612 A MX2021013612 A MX 2021013612A MX 2021013612 A MX2021013612 A MX 2021013612A MX 2021013612 A MX2021013612 A MX 2021013612A MX 2021013612 A MX2021013612 A MX 2021013612A
Authority
MX
Mexico
Prior art keywords
methods
oligosaccharide compositions
oligosaccharide
compositions
abundance
Prior art date
Application number
MX2021013612A
Other languages
English (en)
Inventor
Christopher Matthew Liu
Jonathan Lawrence
Tatyana Yatsunenko
Madeline Rosini
Max Hecht
Original Assignee
Kaleido Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaleido Biosciences Inc filed Critical Kaleido Biosciences Inc
Publication of MX2021013612A publication Critical patent/MX2021013612A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los aspectos de la invención se refieren a composiciones de oligosacáridos y métodos para preparar las mismas. También se proporcionan métodos para usar composiciones de oligosacáridos como terapias metabólicas del microbioma para reducir los niveles y/o la abundancia de patógenos y para el tratamiento de enfermedades relacionadas.
MX2021013612A 2019-05-08 2020-05-08 Composiciones de oligosacaridos y metodos de uso de las mismas. MX2021013612A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845305P 2019-05-08 2019-05-08
US201962910179P 2019-10-03 2019-10-03
PCT/US2020/032240 WO2020227689A1 (en) 2019-05-08 2020-05-08 Oligosaccharide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021013612A true MX2021013612A (es) 2021-12-10

Family

ID=73051664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013612A MX2021013612A (es) 2019-05-08 2020-05-08 Composiciones de oligosacaridos y metodos de uso de las mismas.

Country Status (12)

Country Link
US (1) US20220233560A1 (es)
EP (1) EP3965776A4 (es)
JP (1) JP2022532066A (es)
KR (1) KR20220007090A (es)
CN (1) CN114126625A (es)
AU (1) AU2020267774A1 (es)
BR (1) BR112021022293A2 (es)
CA (1) CA3138903A1 (es)
IL (1) IL287797A (es)
MX (1) MX2021013612A (es)
SG (1) SG11202112314XA (es)
WO (1) WO2020227689A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113404A (zh) * 2020-07-17 2023-05-12 Dsm营养产品有限责任公司 寡糖组合物及其使用方法
EP4438051A1 (en) * 2023-03-28 2024-10-02 Biome Inc. Microbiome-based composition for preventing and treating multidrug resistant bacterial infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6077303B2 (ja) * 2009-05-07 2017-02-08 タト エ リル アングルディアント フランス ソシエテ パ アクシオンス シンプリフィエ アルファ−（１，２）−分岐アルファ−（１，６）オリゴデキストランを含有する組成物及びアルファ−（１，２）−分岐アルファ−（１，６）オリゴデキストランの製造方法
CA3228950A1 (en) * 2014-07-09 2016-01-14 Dsm Nutritional Products, Llc Oligosaccharide compositions and methods for producing thereof
EP3551194B1 (en) * 2016-12-06 2023-10-18 DSM Nutritional Products, LLC Glycan polymers and related methods thereof
JP2021502338A (ja) * 2017-11-03 2021-01-28 カレイド・バイオサイエンシズ・インコーポレイテッド 感染の治療のためのグリカン調製物
US20230165881A1 (en) * 2020-04-30 2023-06-01 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof for treating viral infections

Also Published As

Publication number Publication date
AU2020267774A1 (en) 2021-12-02
CN114126625A (zh) 2022-03-01
WO2020227689A1 (en) 2020-11-12
CA3138903A1 (en) 2020-11-12
KR20220007090A (ko) 2022-01-18
US20220233560A1 (en) 2022-07-28
SG11202112314XA (en) 2021-12-30
JP2022532066A (ja) 2022-07-13
EP3965776A1 (en) 2022-03-16
WO2020227689A8 (en) 2020-12-30
IL287797A (en) 2022-01-01
EP3965776A4 (en) 2023-08-02
BR112021022293A2 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2017219029A8 (en) COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
SA518391624B1 (ar) Ror- منظمات جاما
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2018015683A (es) Composiciones y métodos para el agotamiento de células.
WO2019084057A3 (en) Compositions and methods for the depletion of cd117+ cells
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2023013435A (es) Composiciones y metodos para expresar otoferlina.
WO2019178487A3 (en) Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
EA201790688A1 (ru) Новые соединения в качестве ингибиторов nik
MX2019002924A (es) Composiciones purificadas de oligosacaridos de leche humana.
WO2020097568A3 (en) Oligosaccharide compositions and methods of use thereof
EP3737379A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF METABOLIC DISEASES
WO2018094300A8 (en) ANTI-GITR ANTIGEN BINDING PROTEINS AND METHODS OF USE
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
AU2020258568A8 (en) CD73 inhibitors
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2021013612A (es) Composiciones de oligosacaridos y metodos de uso de las mismas.
EP4279925A3 (en) Dulaglutide for the treatment of chronic kidney disease
AU2020378127A8 (en) Compounds as CD73 inhibitors
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
MX2024005649A (es) Proteinas quimericas basadas en sirp1a y cd40l.